Healthcare / Medical Instruments & SuppliesSwiss
$50.10
+0.75 (+1.52%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $17.3M · quality 71.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
36/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$299M
P/E
20.9x
↑EV/EBITDA
12.4x
↑ROE
14.9%
↑Gross Margin
62.1%
↑Debt/Equity
0.47
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-3.5%
FCF CAGR
-20.1%
FCF margin
3.2%
FCF / Net income
0.51x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $240.0M · net income $14.9M · FCF $7.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $240.0M | $240.0M | $250.2M | $242.7M | $267.1M |
| Net Income | $14.9M | $14.9M | $20.5M | $11.9M | $26.0M |
| EBITDA | $26.2M | $26.2M | $34.2M | $23.8M | $39.9M |
| EPS | 2.50 | 2.50 | 3.43 | 2.00 | 4.35 |
| Gross Margin | 62.1% | 62.1% | 62.7% | 60.5% | 63.0% |
| Operating Margin | 8.8% | 8.8% | 10.7% | 8.1% | 13.1% |
| Net Margin | 6.2% | 6.2% | 8.2% | 4.9% | 9.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.47 | 0.47 | 0.37 | 0.46 | 0.42 |
| Current Ratio | 1.64 | 1.64 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $7.7M | $7.7M | $22.8M | $17.3M | $15.1M |
| Returns | |||||
| ROE | 14.9% | 14.9% | 18.8% | 12.3% | 23.2% |
| Valuation | |||||
| P/E | 20.87 | 20.87 | 14.81 | 34.20 | 18.60 |
| EV/EBITDA | 12.44 | 12.44 | 9.40 | 18.29 | 12.69 |
| P/B | 2.98 | 2.98 | 2.79 | 4.22 | 4.31 |
| Growth & Yield | |||||
| Revenue Growth | -4.0% | -4.0% | 3.1% | -9.1% | — |
| EPS Growth | -27.1% | -27.1% | 71.5% | -54.0% | — |
| Dividend Yield | 4.0% | 4.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
21.2%
EPS terminal req.
$4.45
Spread vs growth
-48.3%
5Y implied EPS CAGR
16.6%
EPS terminal req.
$5.38
Spread vs growth
-43.7%
10Y implied EPS CAGR
13.2%
EPS terminal req.
$8.66
Spread vs growth
-40.3%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-21.6%
Start / end P/E
19.7x → 20.0x
EPS bridge
3.43 → 2.50
Residual
-0.5%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.